A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome
- PMID: 10856472
- DOI: 10.1016/s0015-0282(00)00535-5
A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome
Abstract
Objective: To compare the endocrine changes in the follicular phase in infertile patients with polycystic ovary syndrome (PCOS) treated with either pulsatile IV GnRH after GnRH-agonist (GnRH-a) down-regulation or clomiphene citrate (CC).
Design: Subgroup analysis within a randomized, controlled, multicenter study.
Setting: Women referred to the Infertility Clinic, Catharina Hospital Eindhoven, The Netherlands.
Patient(s): Twenty-eight infertile patients with PCOS. INTERVENTIONs): Patients were randomly assigned to pulsatile IV GnRH (10-20 microgram/90 min) after GnRH-a down-regulation or CC (50-150 mg; cycle days 3-7). Patients were monitored on alternate days with ovarian sonography and serum concentrations of E(2), LH, and FSH. Serum P and sonography confirmed ovulation.
Main outcome measure(s): Serum concentrations of E(2), LH, and FSH were assessed before treatment was started and after each ovarian sonography.
Result(s): In ovulatory cycles, no statistically significant differences were observed during the follicular phase comparing serum concentrations of E(2), LH, and FSH between the treatments. However, a significant increase in LH occurred in the GnRH group.
Conclusion(s): No significant endocrine differences were observed between GnRH and CC treatment. However, there was a significant increase in the serum LH concentration during the follicular phase in the GnRH group. Increments of LH in the GnRH group may be due to recovery of endogenous LH secretion.
Similar articles
-
Benefits of continuous physiological pulsatile gonadotropin-releasing hormone therapy in women with polycystic ovarian syndrome.Fertil Steril. 1994 Jun;61(6):1027-33. Fertil Steril. 1994. PMID: 8194612 Clinical Trial.
-
Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.Reprod Biomed Online. 2014 Mar;28(3):359-68. doi: 10.1016/j.rbmo.2013.10.019. Epub 2013 Oct 31. Reprod Biomed Online. 2014. PMID: 24456700
-
Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.Fertil Steril. 1996 Jun;65(6):1115-8. doi: 10.1016/s0015-0282(16)58323-x. Fertil Steril. 1996. PMID: 8641482 Clinical Trial.
-
Ovulation and the polycystic ovary syndrome.Aust N Z J Obstet Gynaecol. 1994 Jun;34(3):277-85. doi: 10.1111/j.1479-828x.1994.tb01073.x. Aust N Z J Obstet Gynaecol. 1994. PMID: 7848200 Review.
-
Pharmacology of medications used for ovarian stimulation.Best Pract Res Clin Endocrinol Metab. 2019 Feb;33(1):21-33. doi: 10.1016/j.beem.2018.10.002. Epub 2018 Nov 12. Best Pract Res Clin Endocrinol Metab. 2019. PMID: 30470497 Review.
Cited by
-
Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome.Cochrane Database Syst Rev. 2004;2003(1):CD000412. doi: 10.1002/14651858.CD000412.pub2. Cochrane Database Syst Rev. 2004. PMID: 14973957 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical